share_log

Information Mediary Corp. and Adherence Partner to Launch Revolutionary Digital MMAS Integration for Medication Adherence

Information Mediary Corp. and Adherence Partner to Launch Revolutionary Digital MMAS Integration for Medication Adherence

Information Mediary Corp. 和 Assection 合作伙伴将推出革命性的数字 MMAS 集成
PR Newswire ·  05/06 22:30

Information Mediary Corp (IMC) and Adherence have collaborated to introduce a digitized Morisky Medication Adherence Scale (MMAS), revolutionizing medication adherence management.

Information Mediary Corp(IMC)和Alistence合作推出了数字化的莫里斯基药物依从性量表(MMAS),彻底改变了药物依从性管理。

NEW YORK, May 6, 2024 /PRNewswire/ -- Information Mediary Corp (IMC) and Adherence have collaborated to introduce a digitized Morisky Medication Adherence Scale (MMAS), revolutionizing medication adherence management. This innovative solution signifies a significant advancement in precision and efficiency in patient care.

纽约,2024年5月6日 /PRNewswire/ — Information Mediary Corp(IMC)和Alistence合作推出了数字化的莫里斯基药物依从性量表(MMAS),彻底改变了药物依从性管理。这种创新的解决方案标志着患者护理精度和效率的显著提高。

The Morisky scale plays a crucial role in ensuring patients adhere to their prescribed medications, directly impacting treatment outcomes by preventing disease progression, reducing complications, and enhancing overall health outcomes.

莫里斯基量表在确保患者遵守处方药方面起着至关重要的作用,通过防止疾病进展、减少并发症和改善整体健康状况直接影响治疗结果。

Recognized as the gold standard for assessing medication adherence, the MMAS-4 and MMAS-8 have been referenced in over 31,298 academic journals.

MMAS-4 和 MMAS-8 被公认为评估药物依从性的黄金标准,已被超过 31,298 份学术期刊引用。

This new partnership combines IMC's cutting-edge dose analytics with Adherence's expertise to create a solution that integrates patient-reported MMAS data with objective adherence information. Through this collaboration, IMC will seamlessly integrate MMAS with the CertiScan Adherence Insight Platform, eCAP, and Med-ic, providing partners with a comprehensive suite of tools for advanced adherence monitoring and improved patient outcomes.

这种新的合作伙伴关系将IMC的尖端剂量分析与依从性的专业知识相结合,创建了一种将患者报告的MMAS数据与客观依从性信息相结合的解决方案。通过此次合作,IMC将把MMAS与CertiScan依从性洞察平台、eCAP和Med-IC无缝整合,为合作伙伴提供一套全面的工具,用于高级依从性监测和改善患者预后。

A key focus of this partnership is the development of APIs for third-party platform integration. This initiative will enable industry partners to leverage the benefits of this innovative solution across various healthcare settings.

这种合作关系的主要重点是开发用于第三方平台集成的API。该计划将使行业合作伙伴能够在各种医疗保健环境中利用这种创新解决方案的优势。

Dean Brotzel, CTO of IMC, emphasized, "The digital MMAS integration marks a significant milestone in medication adherence monitoring. By leveraging combined data sources, we are transforming the approach healthcare providers and patients take towards medication adherence."

IMC首席技术官迪恩·布罗策尔强调说:“数字化MMAS集成标志着药物依从性监测领域的一个重要里程碑。通过利用综合数据源,我们正在改变医疗保健提供者和患者在坚持用药方面采取的方法。”

For media inquiries or more information on the groundbreaking collaboration between IMC and Adherence, please contact [email protected] or [email protected]

如需媒体垂询或有关 IMC 与 Afference 之间开创性合作的更多信息,请联系 [email protected] 或 [email protected]

About Information Mediary Corp (IMC): IMC is at the forefront of developing smart packaging solutions that integrate cutting-edge technology to enhance patient safety, medication adherence, and healthcare outcomes.

关于信息媒体公司(IMC): IMC处于开发智能包装解决方案的最前沿,该解决方案整合了尖端技术,以增强患者安全、药物依从性和医疗保健结果。

IMC's Med-ic is the only Smart Dose blister ever submitted with a FDA priority review resulting in a blockbuster drug approval. Over a million smart Med-ic blisters have been used over the past few years to gather valuable adherence data from over 20 million doses in pivotal clinical trials with customers such as AbbVie and Merck. InformationMediary.com

IMC的Med-ic是有史以来唯一一款获得美国食品药品管理局优先审查的智能剂量泡罩,该药品获得了轰动一时的批准。在过去的几年中,在与艾伯维和默沙东等客户进行的关键临床试验中,已使用超过一百万个智能Med-ic泡罩来收集超过2000万剂量的宝贵依从性数据。Informediary.com

About Adherence: The MMAS (Morisky Medication Adherence Scale), developed by Dr. Donald Morisky and several co-authors, is a 4 and 8 item self-report questionnaire that evaluates medication adherence by probing behaviors like medication forgetting or discontinuation. The MMAS is widely applied in healthcare research and clinical practice, aiding in the identification of patients at risk of non-adherence and guiding the customization of adherence interventions.

关于依从性: 由唐纳德·莫里斯基博士和几位合著者开发的MMAS(莫里斯基药物依从性量表)是一份4项和8项的自我报告问卷,通过探测遗忘用药或停药等行为来评估药物依从性。MMAS 广泛应用于医疗保健研究和临床实践,有助于识别存在不依从风险的患者,并指导依从性干预措施的定制。

Adherence serves as the catalyst with pharmaceutical firms, telehealth initiatives, and IT platforms seamlessly integrating MMAS into their systems and procedures. MMAS is intricately woven into defined protocols for standards of care, endpoints and outcome measures in clinical trials, medication therapy management, and patient intake processes. adherence.cc

依从性是制药公司、远程医疗计划和IT平台将MMA无缝集成到其系统和程序中的催化剂。MMAS 错综复杂地融入了临床试验、药物治疗管理和患者入院过程中的护理标准、终点和结果衡量标准的既定协议中。adherence.cc

Press contact:

新闻联系人:

Joanne Watters
6137458400

乔安妮·沃特斯
6137458400

SOURCE Information Mediary Corp.

来源信息 Mediary Corp.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发